A novel drug named idroxioleic acid, or 2-OHOA, derived from oleic acid found in olive oil, has shown promise in treating glioblastoma, a deadly form of brain cancer. An early trial revealed encouraging results, with about a quarter of the 54 participants responding positively to the medication when taken orally mixed with water three times a day. One participant even lived for more than three years after the diagnosis.

Dr. Michele Afif, CEO of the Brain Tumour Charity, expressed optimism about the upcoming Phase 3 trial for newly diagnosed glioblastoma patients in London, stressing the urgency for improved treatments for this challenging disease. A cancer research center in the UK is in the process of recruiting over 200 patients for the trial after the success of the initial study.

Michele Treen, a 42-year-old participant diagnosed with glioblastoma in March 2023, shared her positive experience with 2-OHOA, stating that she was able to enjoy life and travel across Europe with her family despite her diagnosis. The medication works by altering the walls of tumor cells to halt the cancer's growth and spread, offering hope for those facing this devastating disease.